St. Judes Reports Promising results from first prenatal therapy for spinal muscular atrophy
On Feb. 19, 2025, scientists at St. Jude Children’s Research Hospital report results from a promising new approach…
-
-
Biotechnology | COVID-19 | Infectious Disease | Influenza | Measles | Polio | Vaccine
Louisiana Surgeon General ignores science, will not promote vaccines
On Feb. 13, 2025, Ralph L. Abraham, MD, the Louisiana Surgeon General announced that the state will no…
-
CIRM Awards Nearly $100 Million to Boost Discovery, Translational, and Clinical Disease Research
On Jan. 30, 2025, the California Institute for Regenerative Medicine (CIRM) announced it has awarded nearly $100 million…
-
Biotechnology | Diagnostics | Disease | FDA | Therapeutics
FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
On Dec. 20, 2024, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Alhemo®…
-
COVID-19 linked to more heart complications than flu, RSV
On Dec. 16, 2024, a study published in BMC Cardiovascular Disorders shows that pediatric and young adult COVID-19…
-
CIRM Awarded $29.7 Million to Advance rare pediatric disease Clinical Projects
On Nov. 21, 2024, the California Institute for Regenerative Medicine (CIRM) announced it had approved awarding $29.7 million to…
-
FDA Approved First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency
On Nov. 14, 2024, the U.S. Food and Drug Administration approved PTC Therapeutics’ Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated…
-
U.S. FDA Approved Pfizer’s HYMPAVZI™ (marstacimab-hncq) for Treatment of Adults and Adolescents with Hemophilia A or B
On Oct. 11, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved HYMPAVZI™ (marstacimab-hncq)…
-
Biotechnology | Disease | FDA | Neurology | Non-Profit Research | Oncology
FDA Approved Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation
On Aug. 6, 2024, the U.S. Food and Drug Administration (FDA) announced it had approved vorasidenib (Voranigo, Servier…
-
FDA approved new antibiotic for three different uses
On Apr. 3, 2024, the U.S. Food and Drug Administration approved Basilea Pharmaceutica’s Zevtera (ceftobiprole medocaril sodium for…
-
Biotechnology | COVID-19 | Diagnostics | HIV | Infectious Disease | Influenza | Measles | Polio | Vaccine | Women's Health
Global child deaths reached historic low in 2022
On Mar. 12, 2024, the United Nations Inter-agency Group for Child Mortality Estimation (UN IGME) reported that the…
-
Flu vaccination during pregnancy decreased flu hospitalizations and emergency visits in infants younger than 6 months
On Dec. 18, 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced a study that showed…
-
CDC | Life Science History | Measles | WHO
Global measles threat continued to grow as another year passed with millions of children unvaccinated
On Nov. 16. 2023, the U.S. Centers for Disease Control and Prevention (CDC) announced that Following years of…
-
FDA approved first treatment for patients with rare inherited blood clotting disorder
On Nov. 9, 2023, the U.S. Food and Drug Administration approved ‘ Takeda PharmaceuticalsVAdzynma, the first recombinant (genetically…
-
U.S. CDC reported high rates of child flu hospitalizations recorded in 2022-2023 season
On Oct. 20, 2023, the U.S. Centers for Disease Control and Prevention (CDC) reported that among children and…
-
Purdue named new pediatric cancer research center for the late Tyler Trent
On Oct. 14, 2023, Purdue University ensured that the memory of the former graduate and devoted Boilermaker football…
-
Biotechnology | Disease | FDA | Medicine | Therapeutics
U.S. FDA approved first gene therapy for treatment of patients with Duchenne Muscular Dystrophy
On Jun. 22, 2023, the U.S. Food and Drug Administration (FDA) approved Sarepta Therapeutics’s Elevidys, the first gene…
-
U.S. FDA approved new class of medicines to treat pediatric type 2 diabetes
On Jun. 20, 2023, the U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s Jardiance (empagliflozin) and Synjardy…
-
Biotechnology | FDA | Therapeutics | Vaccine
U.S. FDA approved PREVNAR 20, Pfizer’s 20-valent pneumococcal conjugate vaccine for infants and children
On Apr. 27, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®…
-
Biotechnology | FDA | Oncology | Radiology | Stem Cell
U.S. FDA approves cell therapy for patients with blood cancers to reduce risk of infection after stem cell transplantation
On Apr. 17, 2023, the U.S. Food and Drug Administration (FDA) approved Gamida Cell’s Omisirge (omidubicel-onlv), a substantially…
-
Pfizer RSV vaccine 82% effective vs severe infection in infants, final data showed
On Apr. 5, 2023, Pfizer announced that experimental respiratory syncytial virus (RSV) vaccine was 82% effective in preventing…
-
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
-
Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray
On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…
-
Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…
-
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
-
Biotechnology | FDA | Oncology | Therapeutics
FDA granted approval to atezolizumab for alveolar soft part sarcoma
On Dec. 9, 2022, the U.S. Food and Drug Administration (FDA) approved Genentech’s atezolizumab (Tecentriq) for adult and…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Biotechnology | Disease | FDA | Therapeutics
FDA approved first drug that can delay onset of Type 1 Diabetes
On Nov. 17, 2022, the U.S. Food and Drug Administration (FDA) approved Tzield (teplizumab-mzwv) injection to delay the…
-
FDA approved first cellbBased gene therapy to treat adult and pediatric patients with Beta-thalassemia
On Aug. 17, 2022, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel) developed by bluebird bio,…
-
Novavax filed supplement to a New Drug submission in Canada for Nuvaxovid COVID-19 vaccine for adolescents
On Jun. 23 2022, Novavax announced the filing of a Supplement to a New Drug Submission with Health…
